Hopper indirectly controls ALA too. iNKT was licenced to ALA...

Hopper indirectly controls ALA too. iNKT was licenced to ALA through him. Not sure what the buyer, most likely the Merchant Fund, is seeing in ALA.

CHM's CDH17, the world's first CAR-T directly targeting solid cancers is as least as spectacular as the iNKT technology, based on that alone CHM should be valued AUD 150m too. Not even considered CHM's flagship, CHM 1101, which so far outperforms the world leading GBM treatments and is suitable to treat children too. All that again for almost ZERO value. Either ALA totally crazy overvalued or CHM totally crazy undervalued.

First in line at 2.5c, expecting that to get filled soon.

Thanks to, most likely, yesterdays' traders.

GLTA